Sydney Lupkin

The agency says it took a look at many factors, including the drug manufacturer's inventory data, projected demand. It says it also spoke to patients, healthcare providers, and compounding pharmacies. Bottom line, the agency said it thinks Eli Lilly can make enough. Lilly said in a statement that the FDA decision reflects the company's hard work to expand its manufacturing capacity.

and meet patient needs. So compounding pharmacies will need to stop making and selling the compounded versions in February or March, depending on their size.

and meet patient needs. So compounding pharmacies will need to stop making and selling the compounded versions in February or March, depending on their size.

and meet patient needs. So compounding pharmacies will need to stop making and selling the compounded versions in February or March, depending on their size.

Yes, though the exact number is hard to pin down. I've heard from lots of patients who consider them a lifeline, and that's because many health insurers won't cover the drugs for weight loss. Medicare, for instance, is banned from covering drugs for weight loss because of an old law written at a time when having obesity was considered more of a personal failure than a health condition.

Yes, though the exact number is hard to pin down. I've heard from lots of patients who consider them a lifeline, and that's because many health insurers won't cover the drugs for weight loss. Medicare, for instance, is banned from covering drugs for weight loss because of an old law written at a time when having obesity was considered more of a personal failure than a health condition.

Yes, though the exact number is hard to pin down. I've heard from lots of patients who consider them a lifeline, and that's because many health insurers won't cover the drugs for weight loss. Medicare, for instance, is banned from covering drugs for weight loss because of an old law written at a time when having obesity was considered more of a personal failure than a health condition.

That means people without coverage will have to pay the full sticker price for the name brand drugs, and that's unaffordable for a lot of people who've turned to the cheaper compounded versions of the drugs.

That means people without coverage will have to pay the full sticker price for the name brand drugs, and that's unaffordable for a lot of people who've turned to the cheaper compounded versions of the drugs.

That means people without coverage will have to pay the full sticker price for the name brand drugs, and that's unaffordable for a lot of people who've turned to the cheaper compounded versions of the drugs.

Some are stockpiling the compounded drugs, you know, while they can. I checked in with Mary Struski, an Arizona woman who told me a few weeks ago about how she lost 50 pounds so far on compounded terzepatide. She says she and her nurse practitioner settled on a plan to buy enough terzepatide to get her through until about April.

Some are stockpiling the compounded drugs, you know, while they can. I checked in with Mary Struski, an Arizona woman who told me a few weeks ago about how she lost 50 pounds so far on compounded terzepatide. She says she and her nurse practitioner settled on a plan to buy enough terzepatide to get her through until about April.

Some are stockpiling the compounded drugs, you know, while they can. I checked in with Mary Struski, an Arizona woman who told me a few weeks ago about how she lost 50 pounds so far on compounded terzepatide. She says she and her nurse practitioner settled on a plan to buy enough terzepatide to get her through until about April.

And after that, she isn't sure, but she says she needs to find a way to keep taking the medicine.

And after that, she isn't sure, but she says she needs to find a way to keep taking the medicine.

And after that, she isn't sure, but she says she needs to find a way to keep taking the medicine.

Her health is better, and she says she's free of the anxiety that came with eating. She's thinking about what she wants to accomplish in 2025.

Her health is better, and she says she's free of the anxiety that came with eating. She's thinking about what she wants to accomplish in 2025.

Her health is better, and she says she's free of the anxiety that came with eating. She's thinking about what she wants to accomplish in 2025.

You know, it could because the FDA just approved ZepBound as the first drug treatment for moderate to severe obstructive sleep apnea in patients who have obesity. Obstructive sleep apnea is a condition in which someone temporarily pauses breathing in their sleep because their upper airway collapses. It is more common among people who have obesity.